ACAD- Acadia Pharmaceuticals Inc.

Name: Acadia Pharmaceuticals Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Acadia Pharmaceuticals Inc. (ACAD) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 15 sells. ACAD is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
CFO	Schneyer Mark C.	66.1K	$1.90M	-
10%	Baker Bros. Advisors LP	32.0K	$919.9K	-
VP	Thompson Elizabeth H.Z.	19.0K	$545.9K	-16,558
CEO	Owen Adams Catherine	14.8K	$425.4K	-
Other	Kihara James	13.1K	$376.1K	-

Activity

Buys and sells only

Transactions

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jul 30, 2026	Thompson Elizabeth H.Z.	EVP, Head Of Research &Dev	Sale+OE	16,558	$26.13	$432,662.54	-30.3%	-	-
Jun 26, 2026	Kihara James62	Principal Accounting Officer	Sell	11,421	$26.08	$297,912.22	-46.6%	-	-
May 4, 2026	Schneyer Mark C.59	EVP, Chief Financial Officer	Sale+OE	3,506	$21.79	$76,395.74	-5.0%	+16.6%	-
May 4, 2026	Kihara James62	Principal Accounting Officer	Sale+OE	1,332	$21.79	$29,024.28	-4.4%	+16.6%	-
Mar 26, 2026	Kihara James62	Principal Accounting Officer	Sale+OE	1,942	$21.57	$41,895.26	-2.4%	+8.8%	-
Mar 26, 2026	Schneyer Mark C.59	EVP, Chief Financial Officer	Sale+OE	7,385	$21.55	$159,135.88	-4.0%	+8.8%	-
Mar 25, 2026	Owen Adams Catherine	Chief Executive Officer	Sale+OE	11,641	$21.47	$249,932.27	-44.0%	+2.7%	-
Mar 25, 2026	Thompson Elizabeth H.Z.	EVP, Head Of Research &Dev	Sale+OE	3,435	$21.47	$73,749.45	-51.2%	+2.7%	-
Mar 25, 2026	Rhodes Jennifer J93	EVP, Chief Legal Officer, Sec	Sale+OE	3,844	$21.47	$82,530.68	-25.4%	+2.7%	-
Nov 18, 2025	Schneyer Mark C.59	EVP, Chief Financial Officer	Sale+OE	10,262	$23.69	$243,113.96	-16.1%	-3.6%	-

Page 1Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC